SUMMARY
Background Current testing guidelines for COVID-19 substantially underestimates the spread of SARS-CoV-2 in dense urban populations. Granular estimates of infection are important for understanding population-level immunity. We examined seroprevalence of anti-SARS-CoV-2 antibodies in Pune city in India and its implication for protective immunity.
Methods Seroprevalence was estimated during July 20-August 5, 2020 from 1659 randomly selected individuals recruited from five administrative Pune sub-wards (combined population 366,984). Prevalence of anti-SARS-CoV-2 spike protein antibodies were estimated and along with correlates of virus neutralisation.
Findings Seropositivity was extensive (51·3%; 95%CI 39·9-62·4) but varied widely in the five localities tested, ranging from 35·8% to 66·4%. Seropositivity was higher in crowded living conditions in the slums (OR 1·91), and was lower in those 65 years or older (OR 0·59). The infection-fatality ratio was estimated at 0.28%. Post survey, COVID-19 incidence was lower in areas noted to have higher seroprevalence. Substantial virus-neutralising activity was observed in seropositive individuals, but with considerable heterogeneity in the immune response and possible age-dependent diversity in the antibody repertoire.
Interpretation Despite crowded living conditions having facilitated widespread transmission, the variability in seroprevalence in localities that are in geographical proximity indicates a heterogenous spread of infection. Declining infection rates in areas with high seropositivity suggest population-level protection and is supported by substantial neutralising activity in asymptomatically infected individuals. The heterogeneity in antibody levels and neutralisation capacity indicates the existence of immunological sub-groups of functional interest.
Funding Persistent Foundation, Pune, India
Evidence before this study We searched the literature (upto 2 Nov 2020), using the terms “seroprevalence”, “serosurveillance”, “seroepidemiology”, “immune response”, “seroconversion” and “SARS-CoV-2,” without any article type restrictions, and selected only population- or community-level seroprevalence studies for collecting background information. The survey of literature indicated that community serosurveys for SARS-CoV-2 in LICs and LMICs have been limited and have largely reported correlations of seroprevalence with demographic factors. There are no reports of protective immunity-associated characteristics in community surveillance settings from LMIC/LICs. In fact, such studies from the global North are also limited. The existing evidence thus lacks granular details critical to understand community-level heterogeneities, and provides limited epidemiological data without meaningful immunobiological correlates.
Added value of this study This is the first systematic study (at the time of submission) from a LMIC reporting community SARS-CoV-2 sero-surveillance of high granularity alongside estimation of correlates of immune protection. We estimated seroprevalence as well as serological correlates of protection in a cross-sectional cohort of 1659 asymptomatic participants from five small urban localities in the metropolitan city of Pune, India. IgG seroprevalence was determined against the receptor-binding-domain (RBD) of the SARS-CoV-2 spike protein, to aid correlation with immune protection since RBD is the predominant target for neutralising antibodies. Large subsets of the sera were also tested for surrogate neutralisation as well as live SARS-CoV-2 virus neutralisation, data not so far reported in community sero-surveillance studies. We identified substantial locality-specific variations in seropositivity levels and infection fatality rates (IFRs), highlighting heterogeneities of infection behaviour even in dense, urban populations often lost in more global analyses. Notably, the incidence of new infections after the sero-sampling period revealed a strong negative association with seropositivity, indicating potential modification of transmission by community immunity. While RBD-specific antibody levels expectedly showed broad correlation with neutralisation capacities, 30% of individuals showed significant departures from this correlation, again underlining significant immune response heterogeneities.
Implications of all the available evidence High seroprevalence in the dense urban localities of the study site, despite a protracted and stringent lockdown, provides a realistic account on transmission dynamics crucial for public health policies in LMICs. Micro-geographic variability within locales, dominated by sub-optimal living conditions, needs to be acknowledged and used to develop measures designed for people in such socio-economic contexts. The heterogeneity of correlation between RBD seropositivity and neutralising capacity, as well as the complex association with age encountered in this study open up a plethora of research questions into epitope dominance and affinity variations in anti-viral antibodies in asymptomatic infection.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI/2020/07/026509
Funding Statement
The study was supported by the Persistent Foundation, Pune, India. The funding agency had no involvement in any aspect of the study. No other funding has been received by the authors or their institutions regarding this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Ethics Committee of SPPU (SPPU/IEC/2020/82), IISER Pune (IECHR/Admin/2020/005) and THSTI (THS1.8.1(106))
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint senior author
Data Availability
All data is available on reasonable request.
